Compositions of protein receptor tyrosine kinase inhibitors

1. A compound having a structural formula (IVb.21):

or a salt, ester, or prodrug thereof, wherein

J, K, and M are CH, and L is C—CONR 8 R 9 ;

U 1 , U 2 , and X 3 are independently C(R 20 ) or C(R 20 R 21 );

U 3 is C(R 20 R 21 );

A 4 ′ is C or CR 22 ;

N—U 1 , U 2 —U 3 , and U 3 —X 3 are a single bond;

A 4 ′-X 3 and U 1 —U 2 are independently single or double bond;

Y is O or S;

R 5 is hydrogen, alkyl, arylalkyl, or substituted arylalkyl;

R 8 is hydrogen and R 9 is C 1-6 alkyl substituted with an N-piperazinyl ring which is substituted at the nitrogen atom by phenyl, substituted phenyl, or 5-10 membered heteroaryl; and

R 20 , R 21 , and R 22 are hydrogen.

2. The compound of claim 1 , wherein Y is O.

3. The compound of claim 1 , which is selected from the group consisting of:

4. A pharmaceutical composition, comprising a therapeutically effective amount of a compound of claim 1 , or a salt, ester, or prodrug thereof, and at least one pharmaceutically acceptable vehicle.

5. The pharmaceutical composition of claim 4 , wherein the composition is formulated as: an oral unit dosage form, an intravenous unit dosage form, an intranasal unit dosage form, a suppository unit dosage form, an intradermal unit dosage form, an intramuscular unit dosage form, an intraperitoneal unit dosage form, a subcutaneous unit dosage form, an epidural unit dosage form, a sublingual unit dosage form, or an intracerebral unit dosage form.

6. The pharmaceutical composition of claim 4 , wherein the composition is formulated as: an oral unit dosage form, which is suitable for administration of about 0.001 mg to about 200 mg of the compound per kilogram body weight to a patient in need thereof.

7. The pharmaceutical composition of claim 4 , wherein the composition is formulated as: an intravenous unit dosage form, which is suitable for administration of about 0.01 mg to about 100 mg of the compound per kilogram of body weight to a patient in need thereof.

8. The pharmaceutical composition of claim 4 , wherein the composition is formulated as:

(a) an intranasal unit dosage form, which is suitable for administration of about 0.01 mg to about 1 mg of the compound per kilogram of body weight to a patient in need thereof;

(b) a suppository unit dosage form, which is suitable for administration of about 0.01 mg to about 50 mg of the compound per kilogram of body weight to a patient in need thereof and comprises active ingredient in the range of about 0.5% to about 10% by weight; or

(c) an intradermal, intramuscular, intraperitoneal, subcutaneous, epidural, sublingual, or intracerebral unit dosage form, which is suitable for administration of about 0.001 mg to about 200 mg of the compound per kilogram of body weight to a patient in need thereof.

9. The pharmaceutical composition of claim 4 , which is in a form selected from: tablets, pills, pellets, capsules, powders, lozenges, granules, solutions, suspensions, emulsions, syrups, elixirs, sustained-release formulations, aerosols, and sprays.

10. The pharmaceutical composition of claim 4 , which is in the form of a tablet, a capsule, or an oral liquid preparation.

11. The pharmaceutical composition of claim 5 , wherein the composition is formulated as an oral unit dosage form and further comprises one or more optional agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents, preserving agents, time delay or delay disintegration materials, standard oral vehicles, suitable carriers, excipients, and diluents.

12. The pharmaceutical composition of claim 4 , further comprising: at least one additional active agent selected from the group consisting of: an inhibitor of protein kinase A (PKA), an inhibitor of cAMP signaling, a nonsteroidal anti-inflammatory drug, a prostaglandin synthesis inhibitor, a local anesthetic, an anticonvulsant, an antidepressant, an opioid receptor agonist, a neuroleptic, an agonist of GABA A receptor, an analgesic or anti-cancer agent that acts by a mechanism different from a TrkA antagonist, a benzodiazepine, a barbiturate, a neurosteroid, an inhalation anesthetic, an anesthetic, an anticancer drug, a modulator of mGluR5 receptor, and a combination thereof.

13. The pharmaceutical composition of claim 4 , wherein the compound is selected from the group consisting of:

14. A method of treating pain in a patient suffering therefrom, comprising: administering to the patient a compound of claim 1 , or a salt, ester, or prodrug thereof.

15. The method of claim 14 ,

wherein said pain is selected from the group consisting of: acute pain, chronic pain, inflammatory pain, neuropathic pain, tonic pain, persistent pain, postoperative pain, chemical-induced pain, chemotherapy-induced pain, cancer-pain, drug-induced pain, bone pain, arthritis pain, osteoarthritis pain, fibromyalgia, diabetic neuropathic pain, a generalized pain disorder, pain associated with alcohol-induced hyperalgesia, and a combination thereof.